Transmembrane Glycoprotein Agonist

Cibinetide (ARA290) is an erythropoietin (EPO) derivative that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. ICibinetide can be used in the research of neurological disorders.

BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg⁺ T cells.

Biotinyl-neuropeptide W-23 (human) is a biotinylated Neuropeptide W-23 (human) (HY-P1035). Neuropeptide W-23 (human) is an agonist of NPBW1 (GPR7) and NPBW2 (GPR8).

PSB-18422 is a GPR17 agonist, with an EC₅₀ of 0.0279 μM for humans, 0.47 μM for rats, 0.753 μM for mice, and a human K_i of 1.46 μM. PSB-18422 triggers intracellular calcium mobilization via cross-species activation of GPR17. PSB-18422 can be used in the research of allergic bronchial inflammation.

Cibinetide (ARA290) acetate is an erythropoietin (EPO) derivative that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. ICibinetide acetate can be used in the research of neurological disorders.

Epoetin alfa (Epogen) is a recombinant human erythropoietin whose amino acid sequence and biological activity are identical to those of endogenous erythropoietin (EPO). Epoetin alfa is a direct agonist of the EPO receptor (EPOR) on the surface of erythroid progenitor cells, and promotes the production and maturation of red blood cells. Epoetin alfa can be used for research on myelodysplastic syndrome-related anemia and hematological malignancies.

KHK2840 is a potent CD40 agonist with a K_d value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma.